HUTCHMED's Fanregratinib Shows Strong Phase II Results in Cholangiocarcinoma
Event summary
- HUTCHMED presented pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma (ICC) at the ESMO Gastrointestinal Cancers Congress 2026.
- The study achieved a 42.5% objective response rate (ORR) and a median overall survival (OS) of 16.6 months in pretreated advanced ICC patients with FGFR2 fusions/rearrangements.
- Fanregratinib's New Drug Application (NDA) was accepted for review and granted priority review by the NMPA in December 2025.
- The trial, conducted across 53 sites in China, demonstrated a manageable safety profile with 48.3% of patients experiencing Grade 3 or greater drug-related adverse events.
The big picture
HUTCHMED's Phase II data for fanregratinib represents a significant milestone in the targeted treatment of intrahepatic cholangiocarcinoma, a rare and aggressive cancer with limited therapeutic options. The strong clinical results position fanregratinib as a potential new standard of care for patients with FGFR2-altered ICC, addressing a critical unmet need in gastrointestinal oncology. The priority review status granted by the NMPA underscores the urgency and importance of bringing this innovative therapy to market.
What we're watching
- Regulatory Approval
- Whether the NMPA will approve fanregratinib based on the Phase II data and grant it market access for advanced ICC.
- Commercialization Strategy
- How HUTCHMED plans to position fanregratinib in the competitive landscape of targeted therapies for ICC.
- Global Expansion
- The pace at which HUTCHMED can secure regulatory approvals and commercialize fanregratinib in other major markets beyond China.